Liquid biopsy test for early breast cancer treatment response
Part of Cancer, Skin clinical trials.
This study tests if a simple blood test (liquid biopsy) can track how well your breast cancer responds to treatment before surgery. It is for people newly diagnosed with early-stage breast cancer who will receive chemotherapy or other drugs first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been newly diagnosed with stage I, II, or III breast cancer.
- Your cancer type is hormone receptor-positive/HER2-negative, HER2-positive (any hormone status), or triple-negative.
- Your doctor has decided you will receive drug treatment (like chemo or targeted therapy) before surgery.
- You have not had any previous treatment for this breast cancer.
- You have not had another cancer in the last 5 years (except for low-risk cancers that are cured).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study collects small tissue samples from your breast cancer before, during, and after chemotherapy and immunotherapy to identify early signs of how well the treatment is working. The goal is to better predict treatment response and improve outcomes for patients with triple-negative or high-risk hormone-positive breast cancer.
This trial uses a simple blood test (liquid biopsy) and imaging to look for early signs that triple-negative breast cancer has returned after treatment. It is for people who had stage II or III cancer, went through chemotherapy before surgery, and still had cancer left after surgery.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This trial tests a blood test that looks for chemical changes in DNA to help diagnose breast cancer. It may offer a simpler way to detect cancer without needing a tissue sample.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
Hear when a new Early Breast Cancer (EBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.